Pembrolizumab for relapsed or refractory Hodgkin lymphoma. Issue 6 (June 2021)

Record Type:: Journal Article
Title:: Pembrolizumab for relapsed or refractory Hodgkin lymphoma. Issue 6 (June 2021)
Main Title:: Pembrolizumab for relapsed or refractory Hodgkin lymphoma
Authors:: Pulsoni, Alessandro
Abstract:
Is Part Of:: Lancet oncology. Volume 22:Issue 6(2021)
Journal:: Lancet oncology
Issue:: Volume 22:Issue 6(2021)
Issue Display:: Volume 22, Issue 6 (2021)
Year:: 2021
Volume:: 22
Issue:: 6
Issue Sort Value:: 2021-0022-0006-0000
Page Start:: e234
Page End:
Publication Date:: 2021-06
Subjects:: Oncology -- Periodicals
Neoplasms -- Periodicals
Cancérologie -- Périodiques
Oncologie
Oncology
Periodicals
Electronic journals
616.994005
Journal URLs:: http://www.sciencedirect.com/science/journal/14702045 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S1470-2045(21)00251-5 ↗
Languages:: English
ISSNs:: 1470-2045
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 5146.090000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 18250.xml